Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 346 to 360 of 553 results for women's health

  1. Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer (TA746)

    Evidence-based recommendations on nivolumab (Opdivo) as a possible treatment for completely resected oesophageal or gastro-oesophageal junction cancer in adults.

    Technology appraisal guidance
    Published
    17 November 2021
    View recommendations

    Sections for TA746

  2. Fungitell for antifungal treatment stratification (MIB118)

    NICE has developed a medtech innovation briefing (MIB) on Fungitell for antifungal treatment stratification .

    Medtech innovation briefing
    Published
    31 August 2017

  3. Shiley Endotracheal Tube with TaperGuard Cuff for intensive care patients at risk of ventilator‑associated pneumonia (MIB22)

    NICE has developed a medtech innovation briefing (MIB) on the Shiley Endotracheal Tube with TaperGuard Cuff .

    Medtech innovation briefing
    Published
    2 March 2015

  4. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (TA329)

    Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.

    Technology appraisal guidance
    Published
    25 February 2015
    View recommendations

    Sections for TA329

  5. Impact of neonatal infection on the baby's family: What is the impact of neonatal infection on the health-related quality of life of the baby's family?

    infection on the baby's family: What is the impact of neonatal infection on the health-related quality of life of the baby's family? Any...

    Research recommendation
    Published
    6 August 2021

  6. eazyplex SuperBug kits for detecting carbapenemase-producing organisms (MIB94)

    NICE has developed a medtech innovation briefing (MIB) on eazyplex SuperBug kits for detecting carbapenemase-producing organisms .

    Medtech innovation briefing
    Published
    7 February 2017

  7. Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (TA263)

    Evidence-based recommendations on bevacizumab (Avastin), with capecitabine, for treating metastatic breast cancer in adults.

    Technology appraisal guidance
    Published
    22 August 2012
    View recommendations

    Sections for TA263

  8. EarlySense for heart and respiratory monitoring and predicting patient deterioration (MIB49)

    NICE has developed a medtech innovation briefing (MIB) on EarlySense for heart and respiratory monitoring and predicting patient deterioration

    Medtech innovation briefing
    Published
    22 January 2016

  9. Early pregnancy assessment units: A national evaluation of early pregnancy assessment unit service provision should be carried out to identify factors affecting outcomes. Factors should include whether care is provided in a dedicated unit, staffing configuration and opening hours of dedicated services. Outcomes should include both process (service) outcomes and pregnancy-related outcomes. Data collected should be used to analyse the cost effectiveness of early pregnancy assessment units compared with other models of care.

    of early pregnancy assessment units in improving physical and emotional health compared with services provided outside of a dedicated...

    Research recommendation
    Published
    17 December 2021

  10. KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication: early value assessment (HTG694)

    Early value assessment (EVA) guidance on KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication.

    HealthTech guidance
    Published
    26 September 2023
    View recommendations

    Sections for HTG694

  11. Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer (TA1060)

    Evidence-based recommendations on osimertinib (Tagrisso) with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    8 May 2025

    Sections for TA1060

  12. Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over (TA1003)

    Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for transfusion-dependent beta-thalassaemia in people 12 years and over.

    Technology appraisal guidance
    Published
    11 September 2024
    View recommendations

    Sections for TA1003

  13. Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma (TA874)

    Evidence-based recommendations on polatuzumab vedotin (Polivy) with rituximab, cyclophosphamide, doxorubicin and prednisolone for untreated diffuse large B-cell lymphoma in adults.

    Technology appraisal guidance
    Published
    1 March 2023
    View recommendations

    Sections for TA874

  14. Osteoarthritis in over 16s: diagnosis and management (NG226)

    This guideline covers the diagnosis, assessment and non-surgical management of osteoarthritis. It aims to improve management of osteoarthritis and the quality of life for people with osteoarthritis.

    NICE guideline
    Published
    19 October 2022
    View recommendations

    Sections for NG226

  15. Fostamatinib for treating refractory chronic immune thrombocytopenia (TA835)

    Evidence-based recommendations on fostamatinib (Tavlesse) for chronic refractory chronic immune thrombocytopenia in adults.

    Technology appraisal guidance
    Published
    19 October 2022
    View recommendations

    Sections for TA835